J
2025
Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?
EID, Michal; Markéta BEDNAŘÍKOVÁ; Jakub VLAŽNÝ; Jitka HAUSNEROVÁ; Renata TASLEROVÁ et. al.
Basic information
Original name
Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?
Authors
EID, Michal; Markéta BEDNAŘÍKOVÁ; Jakub VLAŽNÝ; Jitka HAUSNEROVÁ; Renata TASLEROVÁ; Sára VILMANOVÁ; Martina JELÍNKOVÁ; Alena HOMOLOVÁ; Martin GRYC; Jakub TRIZULJAK; Zdeněk PAVLOVSKÝ; Štěpán TUČEK; Dagmar BRANČÍKOVÁ; Monika BRATOVÁ; Tomáš ROHAN; Zdeněk KALA; Zdeněk KRÁL; Jiří MAYER; Adam SVOBODNÍK and Ondřej SLABÝ
Edition
Cancer Medicine, Hoboken, Sons Ltd. 2025, 2045-7634
Other information
Type of outcome
Article in a journal
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
Organization
Lékařská fakulta – Repository – Repository
EID Scopus
2-s2.0-105012466693
Keywords in English
biomarkers; cancer genetics; next-generation sequencing; target therapy
Links
LM2018132, research and development project. LX22NPO5102, research and development project. MUNI/A/1685/2024, interní kód Repo. CZECRIN IV, large research infrastructures.
In the original language
gt;= 1.3 was observed in 29 (41.4%) of the 70 evaluable pretreated patients.ConclusionThis is the first study to report on a real-world MTB cohort from the Czech Republic, demonstrating a diagnostic yield comparable to previously published studies, good availability of recommended drugs, and clinical benefit in evaluable patients.
Displayed: 18/12/2025 09:26